Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 28 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 |
| clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07256353 | Allogeneic UCB-derived CAR-T for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06849401 | The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 15, 2025 | clinicaltrials |
| NCT06876701 | The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults | not yet recruiting | Early Phase 1 | 10 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06654206 | Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients | not yet recruiting | Early Phase 1 | 40 | University of SalamancaOTHER | 0 | Feb 19, 2025 | clinicaltrials |
| NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. | not yet recruiting | Early Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | not yet recruiting | Early Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials